Cite

HARVARD Citation

    Doz, F. et al. (2022). Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-oncology. 24 (6), pp. 997-1007. [Online]. 
  
Back to record